1. ADC Therapeutics SA. ZYNLONTA™ (loncastuximab tesirine-lpyl); US prescribing information. 2021. https://adctherapeutics.com/. Accessed 2 Jun 2021.
2. Makita S, Tobinai K. Antibody therapy targeting CD19 for B-cell non-Hodgkin’s lymphoma. Ann Oncol. 2018;29(5):1086–9.
3. US Food & Drug Administration. FDA grants accelerated approval to loncastuximab tesirine-lpyl for large B-cell lymphoma [media release]. 23 Apr 2021. https://www.fda.gov/.
4. ADC Therapeutics SA. ADC Therapeutics and Overland Pharmaceuticals announce formation of Overland ADCT BioPharma to develop and commercialize Lonca and other ADCs for hematologic and solid tumor indications in Greater China and Singapore [media release]. 14 Dec 2020. http://www.adctherapeutics.com.
5. ADC Therapeutics SA. ADC Therapeutics and Freenome enter biomarker development collaboration [media release]. 26 Aug 2019. www.adctherapeutics.com.